Skip to main content
. 2022 Mar 16;14(3):649. doi: 10.3390/pharmaceutics14030649

Table 2.

Treatment of hUC-MSCs-sEVs on CB-treated HSkMCs.

Group Description 2-DG (10 mM)
1 HSkMCs only (Blank) No
2 HSkMCs only (Normal control) 10 μL
3 HSkMCs + 1 μM Insulin (Positive control) 10 μL
4 HSkMCs + 0.5 μM CB + 1 μM Insulin 10 μL
5 HSkMCs + 0.5 μM CB + 1 μM Insulin + 20 μg/mL hUC-MSC-sEVs 10 μL